Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01177683
Title Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Sherif Farag, MB, BS
Indications

multiple myeloma

Therapies

Bendamustine + Bortezomib + Pegylated liposomal-doxorubicin

Filgrastim

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Indiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202 United States Details
IU Health Central Indiana Cancer Centers Indianapolis Indiana 46219 United States Details
Community Regional Cancer Center Indianapolis Indiana 46256 United States Details
IU Health Arnett Cancer Center Lafayette Indiana 47904 United States Details
Metro Health Cancer Care Wyoming Michigan 49519 United States Details
University Hospitals Seidman Cancer Center Cleveland Ohio 44106 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field